Haemonetics Corporation (HAE)
Official siteHEALTHCARE • MEDICAL DEVICES • NYSE
Market Cap: $5.60B
Last updated: Nov 17, 2026 at 11:06 AM ET
Haemonetics Corporation (HAE) P/E Ratio & Valuation History
Haemonetics (HAE) trades at 23.9x trailing earnings and 4.0x sales. Its P/E of 23.9x is above its 5-year median of 21.0x. Its forward P/E is 23.0x. The median P/E across 9 similar companies is 31.1x.
Current Multiples
Its forward P/E is below its trailing P/E, which implies earnings per share about 3.9% higher over the next year. Its free cash flow yield is 5.4%.
| Multiple | Value |
|---|---|
| P/E (trailing) | 23.9x |
| Forward P/E | 23.0x |
| Price to sales | 4.0x |
| Price to book | 6.1x |
| EV/EBITDA | 25.3x |
| Price to FCF | 18.5x |
| EV/FCF | 21.4x |
| PEG | 1.9 |
| FCF yield | 5.4% |
Historical Medians
Against its 10-year medians, its P/E is 10.2% below 26.6x, its P/S is 14.3% above 3.5x and its P/B is 24.5% above 4.9x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/E | 23.9x | 21.0x | 26.6x |
| P/S | 4.0x | 3.1x | 3.5x |
| P/B | 6.1x | 4.4x | 4.9x |
Valuation History
Over the 10 year ends shown, its P/E ranged from 16.3x in 2025 to 46.0x in 2020. 2025 was the lowest of those years.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $80.15 | 16.3x | 2.9x | 4.1x |
| 2024 | $78.08 | 18.5x | 2.9x | 4.3x |
| 2023 | $85.51 | 22.2x | 3.4x | 4.6x |
| 2022 | $78.65 | 27.0x | 3.6x | 5.1x |
| 2021 | $53.04 | 22.1x | 2.8x | 3.7x |
| 2020 | $118.75 | 46.0x | 6.8x | 8.4x |
| 2019 | $114.90 | 35.6x | 5.9x | 10.1x |
| 2018 | $100.05 | 45.3x | 5.5x | 8.0x |
| 2017 | $58.08 | 31.9x | 3.4x | 3.7x |
| 2016 | $40.20 | 26.6x | 2.3x | 2.7x |
GNG Valuation
| GNG view | Fairly valued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About HAE
What is HAE's forward P/E ratio?
Haemonetics has a forward P/E ratio of 23.0x.
Is HAE stock overvalued?
GNG's valuation label for HAE is Fairly valued. Its P/E of 23.9x compares with a median of 31.1x across 9 similar companies.
What is HAE's price to sales ratio?
Haemonetics has a price to sales ratio of 4.0x.
What is Haemonetics's average P/E ratio over 5 years?
Haemonetics's median P/E over the last 5 years is 21.0x, from 60 month-end values through Oct 2026.
What is HAE's PEG ratio?
Haemonetics has a PEG ratio of 1.9.
HAE pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts